Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
KU Leuven · Fondazione IRCCS Istituto Nazionale dei Tumori · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
234
total citations
- FWCI
- 50.01
- Percentile
- 100%
- References
- 29
Citations per year
Authors
16Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab
- Internal medicine
- Regimen
- Clinical endpoint
- Cancer
- Oncology
- Progressive disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of Defense
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- AAstraZeneca
- CCelgene
- MKMerck KGaA
- LLLes Laboratories Pierre Fabre
- CFCycle for Survival
- BBeiGene
- IIncyte
- MMacroGenics
- SSeagen
- EEisai
- APAstellas Pharma
- SServier
- OPOno Pharmaceutical
- IIpsen
- GGenentech
- FMFoundation Medicine
- NCNational Cancer Institute
- DSDaiichi Sankyo Europe
- CCilag